Key Highlights
- $26 million Series A financing led by Radical Ventures, with full participation from existing investors.
- Strategic collaborations worth over $550 million with AstraZeneca, Bristol Myers Squibb, and Takeda, including royalties.
- Focus on generative design of drugs targeting multipass membrane proteins like GPCRs, enhancing drug precision and function.
Source: Business Wire
Notable Quotes
- “We are unlocking new opportunities to build highly selective drugs…with a degree of structural precision not previously possible,” – Surge Biswas, Co-Founder and CEO at Nabla Bio
- “That’s an untapped therapeutic opportunity and why several leading pharmaceutical companies have collaborated with us,” – Frances Anastassacos, Co-Founder at Nabla Bio
- “Generative AI and large language models are poised to master the language of proteins…with profound implications for medicine,” – Rob Toews, Partner at Radical Ventures
SoHC's Take
Nabla Bio’s impressive Series A funding and their strategic alliances with some of the world’s top pharmaceutical companies underscore the burgeoning impact of AI in biotechnology. By focusing on the challenging arena of multipass membrane proteins, Nabla is set to transform the landscape of therapeutic development. These proteins, vital to cell behavior and notoriously difficult to target, represent a significant opportunity for the advancement of precision medicine. Nabla’s innovative approach combines cutting-edge AI with practical biotechnology applications, demonstrating a robust potential for future drug discovery and development, especially as they move towards clinical therapies with these novel technologies.
